Brind.

Comparison of Fortress Biotech and Theravance Biopharma Financial Metrics

1 report, 1 independent Updated Sun 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

A comparison of Fortress Biotech and Theravance Biopharma showed that Theravance Biopharma has higher revenue and earnings, while Fortress Biotech trades at a lower price-to-earnings ratio. Regarding risk, Theravance Biopharma has a beta of 0.25, indicating lower volatility than the S&P 500, compared to Fortress Biotech's beta of 1.19. Fortress Biotech has a higher percentage of company insider ownership at 28.5%, compared to 7.6% for Theravance Biopharma.

From themarketsdaily.com

Why it matters

Some supportBrind's analysis of the reports

The comparison highlights differences in the financial profiles of these two small-cap healthcare companies, particularly concerning valuation and risk exposure. These metrics influence how investors perceive the relative affordability and market stability of each stock.

From themarketsdaily.com

Who's involved

  • Fortress BiotechSubject of the financial comparison and recipient of a 'buy' rating from Citigroup.
  • CitigroupAmerican investment bank that issued and reaffirmed a 'buy' rating on Fortress Biotech shares.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped